Industry news that matters to you.  Learn more

Archives for March 2012

NextGen Files for Intellectual Property on Dementia Biomarkers

NextGen Group Plc (AIM: NGG), an AIM listed company providing biomarker discovery services and diagnostic assay development, announces that its subsidiary, NextGen Sciences Dx (NGSDx), has filed for intellectual property (IP) on a combination of protein biomarkers with the potential for diagnosing changes in cognition for patients with early-stage dementia.

NephroCheck Test Aimed at Providing Risk Assessment Information for ICU Patients

Astute Medical, Inc., a developer of biomarker-based diagnostics intended to aid physicians in managing critically ill patients, today revealed its first product candidate, the NephroCheck Test, at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) being held in Brussels, Belgium. The novel test, which will be launched in Europe later this year, is intended to aid in the risk assessment for acute kidney injury (AKI) in critically ill patients, a condition with mortality rates approaching 40 to 80 percent for severely ill patients in intensive care settings (ICU).

Clinical Trial Examining Effects of Antioxidants for Alzheimer Disease on Cerebrospinal Fluid Biomarkers

An antioxidant combination of vitamin E, vitamin C and alpha-lipoic acid (E/C/ALA) was not associated with changes in some cerebrospinal fluid biomarkers related to Alzheimer disease in a randomized controlled trial, according to a study published Online First by Archives of Neurology, one of the JAMA/Archives journals.

P4 Medicine institute, PeaceHealth Launch Partnership to Pilot New Model in Health Care

​PeaceHealth and the P4 Medicine institute (P4Mi) announced a partnership that will ultimately give PeaceHealth providers additional innovative care tools and technologies to predict and potentially delay and/or avoid disease in patients through breakthroughs in genome mapping and molecular diagnostics.

CellMade Targets Inflammatory Biology Products and Services

CellMade, a specialist provider of biomarker and drug discovery support for inflammation research, announces the launch of its new website. Reflecting the company’s leading position in using human cell-based technology to better inform research decisions, the new site features free poster and protocol downloads as well as updated information on the CellInsight™ platform and REACT-lipid™ service. www.cellmade.com looks set to become a primary resource for drug discovery and preclinical researchers working in inflammatory diseases.